Colony-stimulating factors and coxsackievirus B3 myocarditis in mice: Macrophage colony-stimulating factor suppresses acute myocarditis with increasing interferon-α

1995 ◽  
Vol 130 (6) ◽  
pp. 1259-1264 ◽  
Author(s):  
Yuji Hiraoka ◽  
Chiharu Kishimoto ◽  
Hitoshi Takada ◽  
Nario Suzaki ◽  
Kimiyasu Shiraki
2003 ◽  
Vol 75 (1) ◽  
pp. 106-116 ◽  
Author(s):  
Silvia Della Bella ◽  
Stefania Nicola ◽  
Antonio Riva ◽  
Mara Biasin ◽  
Mario Clerici ◽  
...  

2020 ◽  
Author(s):  
Damilola Pinheiro ◽  
Marie-Anne Mahwin ◽  
Maria Prendecki ◽  
Kevin J Woollard

AbstractNeutrophils or heterophils constitute the largest population of phagocytic granulocytes in the blood of mammals and birds. The development and function of neutrophils and monocytes is primarily governed by the granulocyte colony-stimulating factor receptor family (CSF3R/CSF3) and macrophage colony-stimulating factor receptor family (CSF1R/IL34/CSF1) respectively. Using various techniques this study considered how the emergence of receptor:ligand pairings shaped the distribution of blood myeloid cell populations. Comparative gene analysis supported the ancestral pairings of CSF1R/IL34 and CSF3R/CSF3, and the emergence of CSF1 later in tetrapod lineages after the advent of Jawed/Jawless fish. Further analysis suggested that the emergence of CSF3 lead to reorganisation of granulocyte distribution between amphibian and early reptiles. However, the advent of endothermy likely contributed to the dominance of the neutrophil/heterophil in modern-day mammals and birds. In summary, we show that the emergence of CSF3R/CSF3 was a key factor in the subsequent evolution of the modern-day mammalian neutrophil.Impact statementColony-stimulating factors (CSFs) are important for myeloid phagocyte development. The emergence of CSF3/CSF3R in tetrapod lineages has uniquely contributed to physical, functional and structural adaptions observed in mammalian neutrophils.


1991 ◽  
Vol 2 (2) ◽  
pp. 74-88 ◽  
Author(s):  
James Rusthoven

Hematopoietic colony-stimulating factors coordinate the proliferation and maturation of bone marrow and peripheral blood cells during normal hematopoiesis. Most of these factors are now available as recombinant human colony-stimulating factors, and preclinical and clinical testing is proceeding rapidly. Granulocyte and granulocyte/macrophage colony-stimulating factors have been the most extensively studied to date. In human clinical trials, granulocyte colony-stimulating factor improves neutrophil counts and function, reduces episodes of febrile neutropenia, improves neutrophil recovery after disease- or treatment-induced myelosuppression, and reduces the number of serious infections in several neutropenic disease states. Granulocyte/macrophage colony-stimulating factor has similar biological properties but may also improve eosinophil proliferation and function, and platelet cell recovery after myelotoxic bone marrow injury, Interleukin-1 boosts the effects of granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor, but also may promote the resolution of established infections in conjunction with antibiotics. The therapeutic realities and future therapeutic implications of these agents for the therapy of infections, cancer and hemopoietic disorders are discussed.


Sign in / Sign up

Export Citation Format

Share Document